Patient-Focused Drug Development: A New Direction for Collaboration.

Area of Science:

• Pharmacovigilance and Drug Development
• Regulatory Science
• Patient-Centered Outcomes Research

Background:

• The Food and Drug Administration (FDA) initiated Patient-Focused Drug Development (PFDD) to incorporate patient perspectives early in drug development.
• PFDD aims to enhance benefit-risk assessments, inform regulatory review divisions, and improve study endpoints and risk communication.
• This initiative seeks to broaden the application of patient-centered principles beyond the initial 20 conditions under consideration.

Purpose of the Study:

• To summarize current knowledge of the FDA's PFDD initiative.
• To outline implications for patients, researchers, payers, and the biopharmaceutical industry.
• To provide a roadmap for stakeholders to engage with and shape the direction of PFDD.

Main Methods:

• A comprehensive literature search was conducted using PubMed and Google.
• The search included peer-reviewed literature, gray literature, laws, FDA guidance documents, and FDA presentations.
• Keywords focused on "patient-focused drug development" to gather relevant information.

Main Results:

• Current FDA PFDD activities primarily involve disease-specific meetings to gather patient insights.
• Stakeholders widely perceive PFDD as a significant move towards patient centeredness in biopharmaceutical development.
• The initiative is currently limited to 20 specific disease areas.

Conclusions:

• The PFDD initiative holds the potential to fundamentally transform drug development processes.
• Further research is needed to optimize methods for collecting and documenting patient input on disease and treatment options.
• Successful implementation depends on addressing all PFDD objectives and stakeholder engagement.